Cancer

Title
A Study to See if Adding Veliparib and/or Carboplatin to Standard Chemotherapy before Surgery Can Help Shrink Triple-Negative Breast Cancer Faster, and Lower the Risk of the Cancer Coming Back in Other Parts of the Body.
Trial Number
206182041614
Number of Participants
624
Principal Investigator

Kathy S. Albain

M.D.
Hematology/Oncology
Professor
Eligibility

Adult women with histologically confirmed triple-negative invasive breast cancer with a clinical stage T2-4 N0-2 or T1 N1-2, PS 0-1, adequate organ function who have not had any previous anti-cancer treatment for the current breast cancer.

Purpose

The purpose of this study is to see if adding veliparib and/or carboplatin to standard neoadjuvant chemotherapy can help shrink triple negative breast cancer faster, and lower the risk of the cancer coming back in other parts of the body.

Enrollment

(708) 327-1240

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.